Real-World Pseudoprogression: an Uncommon Phenomenon.
Explore this paper's citation graph
- Type
- letter
- Published
- 2018-07-01
- Cited by
- 17
- References
- 16
- Access
- Open access
- OpenAlex
- https://openalex.org/W2809358754
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:49408952
Keywords
Medicine, Pembrolizumab, Docetaxel, Nivolumab, Lung cancer
References
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pseudoprogression and Immune-Related Response in Solid Tumors.
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-related Response Criteria using Unidimentional measurements
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Pseudoprogression and Measurement Variability.
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- Radiologic Pseudoprogression during Anti–PD‐1 Therapy for Advanced Non–Small Cell Lung Cancer
Cited by
- The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer.
- Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
- Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment
- The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
- Role of liquid biopsy for thoracic cancers immunotherapy
- Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
- Pseudoprogression during Immunotherapy in Metastatic Head and Neck Squamous Cell Carcinoma.
- Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
- Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells
- Dual-energy computed tomography as a lower radiation dose alternative to perfusion computed tomography in tumor viability assessment
- Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment
- Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
- Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report
- Cardiothoracic complications of immune checkpoint inhibitors.
- Bildgebung bei Immuntherapie bei Tumorerkrankungen
- Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy.
- Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
- Analysis of hyperprogressive disease due to atezolizumab combined with bevacizumab treatment in patients with advanced hepatocellular carcinoma
- Analysis of hyperprogressive disease due to atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma
Related papers
- Indirect comparison of treating patients with advanced/metastatic melanoma with nivolumab or pembrolizumab — multicenter analysis
- Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab
- Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- Immunotherapy protocols in lung cancer
- Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
- Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
- POSC31 Comparison of Atezolizumab, Nivolumab, and Pembrolizumab in Elderly Cancer Patients over 65 Years of Age